IN2014CN02972A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02972A
IN2014CN02972A IN2972CHN2014A IN2014CN02972A IN 2014CN02972 A IN2014CN02972 A IN 2014CN02972A IN 2972CHN2014 A IN2972CHN2014 A IN 2972CHN2014A IN 2014CN02972 A IN2014CN02972 A IN 2014CN02972A
Authority
IN
India
Prior art keywords
corneal
riboflavin
keratoconus
permeation
guarantee
Prior art date
Application number
Inventor
Fulvio Foschini
Marcello Stagni
Giulio Luciani
Pierre Roy
Original Assignee
Sooft Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sooft Italia Spa filed Critical Sooft Italia Spa
Publication of IN2014CN02972A publication Critical patent/IN2014CN02972A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to an improved formulation of an ophthalmic composition containing riboflavin as cross linking agent of corneal collagen administered by corneal iontophoresis able to guarantee an increased capacity of permeation of riboflavin of the corneal stroma and therefore greater therapeutic efficacy in the treatment of keratoconus.
IN2972CHN2014 2011-10-25 2012-10-24 IN2014CN02972A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000560A ITRM20110560A1 (en) 2011-10-25 2011-10-25 IMPROVED CROSS-LINKING COMPOSITION FOR THE TREATMENT OF KERATOCONUS BY IONTOFORESIS
PCT/IT2012/000324 WO2013061350A1 (en) 2011-10-25 2012-10-24 Improved cross-linking composition delivered by iontophoresis, useful for the treatment of keratoconus

Publications (1)

Publication Number Publication Date
IN2014CN02972A true IN2014CN02972A (en) 2015-07-03

Family

ID=45315962

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2972CHN2014 IN2014CN02972A (en) 2011-10-25 2012-10-24

Country Status (16)

Country Link
US (1) US9439908B2 (en)
EP (1) EP2770979B1 (en)
JP (1) JP5913606B2 (en)
KR (1) KR101837238B1 (en)
AU (1) AU2012327916B2 (en)
BR (1) BR112014009761B8 (en)
CA (1) CA2851331C (en)
EA (1) EA026703B1 (en)
ES (1) ES2546263T3 (en)
IL (1) IL232194A (en)
IN (1) IN2014CN02972A (en)
IT (1) ITRM20110560A1 (en)
MX (1) MX342930B (en)
PT (1) PT2770979E (en)
RS (1) RS54139B1 (en)
WO (1) WO2013061350A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
WO2012095877A1 (en) 2011-01-12 2012-07-19 Sooft Italia Spa Corneal delivery of cross-linking agents by iontophoresis for the treatment of keratoconus and related ophthalmic compositions
EP4420725A2 (en) 2012-03-29 2024-08-28 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
EP2830637B1 (en) 2012-03-29 2024-08-21 Epion Therapeutics, Inc. Compositions and methods for treating or preventing diseases associated with oxidative stress
US9931199B2 (en) * 2014-05-05 2018-04-03 Roberto Gustavo ALBERTAZZI Methods and apparatus for treating keratoconus
JP6933377B2 (en) 2015-07-21 2021-09-08 アヴェドロ・インコーポレーテッドＡｖｅｄｒｏ，Ｉｎｃ． Eye treatment systems and methods using photosensitizers
US10342697B2 (en) 2016-04-13 2019-07-09 Avedro, Inc. Systems and methods for delivering drugs to an eye

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030023228A1 (en) * 2001-07-20 2003-01-30 Parkinson Thomas M. Ocular iontophoretic device and method for using the same
ITRM20070356A1 (en) * 2007-06-26 2008-12-27 Sooft Italia Srl STERILE OCULAR SOLUTION DISPOSABLE AND ITS PRODUCTION PROCEDURE FOR THE CORNEAL CROSS LINKING OF THE KERATOCONO
IT1393402B1 (en) * 2008-08-28 2012-04-20 Sooft Italia Spa USE OF ENHANCER EVENTUALLY WITH RIBOFLAVIN, AS WELL AS RELATIVE OPHTHALMIC COMPOSITIONS FOR CORNEAL CROSS-LINKING OF KERATOCON OR OTHER ECNEASIC CORNEAL PATHOLOGIES
EP2289937A1 (en) 2009-08-24 2011-03-02 Wilfried Stücker Production of monoclonal antibodies in vitro
US20110288466A1 (en) * 2010-04-13 2011-11-24 Avedro, Inc. Systems and methods for activating cross-linking in an eye

Also Published As

Publication number Publication date
JP2014530904A (en) 2014-11-20
JP5913606B2 (en) 2016-04-27
ES2546263T3 (en) 2015-09-22
US20140303173A1 (en) 2014-10-09
BR112014009761B1 (en) 2022-05-24
PT2770979E (en) 2015-10-07
MX342930B (en) 2016-10-19
AU2012327916A1 (en) 2014-05-22
US9439908B2 (en) 2016-09-13
KR101837238B1 (en) 2018-03-09
CA2851331A1 (en) 2013-05-02
EA026703B1 (en) 2017-05-31
RS54139B1 (en) 2015-12-31
KR20140080553A (en) 2014-06-30
CN104023706A (en) 2014-09-03
EP2770979A1 (en) 2014-09-03
WO2013061350A1 (en) 2013-05-02
AU2012327916B2 (en) 2016-04-21
CA2851331C (en) 2019-11-12
MX2014004297A (en) 2014-07-24
ITRM20110560A1 (en) 2013-04-26
BR112014009761A2 (en) 2017-04-25
EP2770979B1 (en) 2015-07-08
EA201490845A1 (en) 2014-07-30
BR112014009761B8 (en) 2022-09-06
IL232194A0 (en) 2014-06-30
IL232194A (en) 2016-09-29

Similar Documents

Publication Publication Date Title
IN2014CN02972A (en)
IL227412A (en) Corneal delivery of cross-linking agents by iontophoresis for the treatment of keratoconus and related ophthalmic compositions
NZ704247A (en) Compositions and treatment for eye diseases and disorders
MX2019000586A (en) Treatment of amd using aav sflt-1.
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
IN2014DN09594A (en)
EA028156B9 (en) Fused heterocyclic compounds as ion channel modulators
EA201590053A1 (en) MODULATORS OF THE COMPLEMENT SYSTEM AND THEIR APPLICATION
MY171920A (en) Prevention and treatment of ocular conditions
WO2013090842A3 (en) Ophthalmic compositions comprising polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymers (soluplus)
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
UA114705C2 (en) Androgen composition for treating an opthalmic condition
MX361858B (en) Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions.
EA201490721A1 (en) Drug for the treatment of diseases of the anterior chamber of the eye, including rebamipid and tear-retaining agent
EP2490700A4 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
MX2024000828A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis.
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
EA201490045A1 (en) DEUTERED 1-PIPERAZINO-3-PHENYLINDANES USED TO TREAT SCHIZOPHRENIA
BR112015004469A2 (en) sirna and its use in methods and compositions for the treatment and / or prevention of eye conditions
MX362485B (en) Novel rock inhibitors.
IN2014DN09437A (en)
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
MX2016005614A (en) Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents.
EP2886112A4 (en) Composition for preventing or treating eye diseases, containing s-allyl-l-cysteine as active ingredient, and pharmaceutical formulation containing same
MX360450B (en) Improvements in and relating to compositions.